More NewsRead More
FDA Determines That Biomerica's Proposed InFoods(R) IBS Clinical Investigation Is a Nonsignificant Risk (NSR) Device Study
July 11, 2016
Biomerica Signs Exclusive License Agreement for Korean Market With Total Value of up to $8.5 Million; Licensee Makes Equity Investment of $1m in Biomerica at $3 per Share
May 26, 2016
All Board Members of Biomerica to Purchase Biomerica Common Stock Shares in the Open Market
April 07, 2016
Biomerica Announced That Its International Patent Application for IBS Was Reviewed by the ISA and All Claims Have Been Deemed Novel and Non-Obvious
March 14, 2016
Biomerica Announces Second Quarter Financial Results
January 15, 2016
category Publishing & Media
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here